Cognitive impairment is frequently observed in patients with MS and changes in the GABAergic system have been associated with cognitive impairment in this population [2,3]. This study aimed to investigate GABA-receptor binding via [11C]FMZ PET. The optimal method of analysis was assessed for [11C]FMZ PET in MS patients and the GABA-receptor binding between cognitively impaired and cognitively unimpaired patients was compared. MS patients (n=17: cognitively impaired, n=11; cognitively unimpaired, n=6) and healthy controls (n=11) underwent 60-minute dynamic PET, using plasma input data. Two models (1-tissue 2-rate-constant (1T2K); 2T4K) measured the influx rate and volume of distribution of 7 brain regions relevant for cognitive function. Akaike information criterion was used to determine the best-fitting model.
By margins, the 2T4K model was preferred over the 1T2K model: in 55.6% of the analysed brain regions, the 2T4K model outperformed the 1T2K model. However, Prof. Hanneke Hulst (Amsterdam UMC, the Netherlands) argued that both models could reliably estimate radiotracer delivery. Mean perfusion rates were significantly lower for cognitively impaired patients (0.29 μL/min) compared with cognitively unimpaired patients (0.33) and healthy controls (0.33). The volume of distribution was higher in cognitively unimpaired patients (5.73 mL of plasma/cm3 of tissue) than in cognitively impaired patients (4.95) and healthy controls (4.87). This implicates a higher GABA-receptor binding in cognitively unimpaired patients.
- Hulst H. [11C]flumazenil positron emission tomography in multiple sclerosis: model validation and clinical applicability in cognitive impairment. LB188, ECTRIMS 2021 Virtual Congress, 13–15 October.
- Benedict RHB, et al. Lancet Neurol. 2020;19(10):860–871.
- Freeman L, et al. Ann Neurol. 2015;78(4):554–567.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« T2 lesions independently predict early conversion to SPMS Next Article
Long-term efficacy data: inebilizumab for NMOSD »
« T2 lesions independently predict early conversion to SPMS Next Article
Long-term efficacy data: inebilizumab for NMOSD »
Table of Contents: ECTRIMS 2021
Featured articles
Preliminary data shows positive results of ATA188 for progressive MS
COVID-19
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Experimental Treatments
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
Treatment Trials and Strategies
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
Biomarkers
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
Imaging
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Eculizumab, satralizumab, or inebilizumab for NMOSD?
Long-term efficacy of satralizumab for NMOSD
Long-term efficacy data: inebilizumab for NMOSD
Progressive MS
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Other
WNT9B-gene variant associated with doubled relapse risk in MS
Melatonin associated with improved sleep quality in MS patients
“Expanded Disability Status Scale 0 is not normal”
Personality trait alterations in MS patients
Related Articles
August 18, 2021
Typing behaviour to remotely monitor clinical MS status
July 30, 2019
New compounds for MS treatment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com